: Cell Culture Congress

Cell Culture Congress

13th Annual
Cell Culture Congress06 - 08 November 2024 | London, UK

Meet with and learn from experts in this community to address the critical technological improvements and innovative strategies needed to improve efficiency in cell line development & bioprocessing.

The Cell Culture Congress includes...

Over 400 cell culture, bioprocessing and cell line development attendees representing global pharmaceutical organisations, leading biotechs and internationally renowned academic institutions.

Over 80 presentations and case studies focussed on the crucial issues in cell line development, bioprocessing technologies and cell culture optimisation.

This Year's Agenda at a Glance

Day One

Day Two

  • Improving efficiency and removing bottlenecks in cell line
  • Clone selection strategies and establishing monoclonality
  • Gene editing techniques for cell line engineering and CRISPR
  • Screening clones for productivity and titer
  • Strategies for single-cell isolation
  • Predicting & Characterizing clones
  • Improving the stability of cell lines via optimized transfection
  • Data for downstream processing
  • Automation & digitalisation
  • High throughput technologies in bioprocessing
  • Improving instrumentation for biopharmaceutical drug production
  • Reducing timelines in bioprocessing biopharmaceutical drug
  • PAT Tools
  • Perfusion cell culture advantages
  • Cell culture media analysis & development
  • Synthetic biology-based approaches to improving cell culture
  • Developing new in vitro bioassays
  • 2D & 3D culture for cell line characterisation
  • Media supply chain
  • Advanced cell culture techniques & technologies for 3D

Day Three

  • Quality Control
  • Facilitating technology transfer for cell-based products
  • Cryopreservation
  • Supply chain
  • Raw material management
  • Analysing and monitoring process to ensure quality
  • Advanced vaccine development
  • Optimized cell line generation for manufacturing of biologics
  • Production of “hard-to-produce” therapeutic proteins
  • Development of bi- and multi-specific antibodies
  • Target validation